Pre-made Ansuvimab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP1 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ansuvimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.
| Products Name (INN Index) | Pre-Made Ansuvimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP1 therapeutic antibody |
|---|---|
| INN Name | Ansuvimab |
| Target | Zaire Ebolavirus GP1 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 5fha:HL/5fhc:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Ridgeback Biotherapeutics |
| Conditions Approved | Zaire ebolavirus infection |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Zaire Ebolavirus GP1 |
| Package |
